Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | BLM | P54132 | 4/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21881191 | 1.00 | CYP2D6 (0.49) | CYP2D6LMNABLMCHRM2CHRM1 | |
| SCHEMBL21881383 | 0.98 | CYP2D6 (0.48) | CYP2D6LMNABLMCHRM2CHRM1 | |
| SCHEMBL7813041 | 0.97 | CYP2D6 (0.49) | CYP2D6LMNABLMCHRM2CHRM1 | |
| SCHEMBL23349257 | 0.86 | SLC6A3 (0.51) | LMNAMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL21881386 | 0.86 | CYP19A1 (0.44) | CYP2D6LMNABLMCHRM2CHRM1 | |
| SCHEMBL14068457 | 0.86 | SLC6A3 (0.51) | LMNAMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL21881480 | 0.85 | TSHR (0.46) | CYP2D6LMNACHRM2CHRM1MEN1 | |
| SCHEMBL21881471 | 0.85 | TSHR (0.46) | CYP2D6LMNACHRM2CHRM1MEN1 | |
| SCHEMBL21881840 | 0.85 | TSHR (0.46) | CYP2D6LMNACHRM2CHRM1MEN1 | |
| SCHEMBL23315550 | 0.84 | CYP19A1 (0.47) | CYP2D6CHRM1CYP1A2CYP2C9CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206724-A1 | ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-06-01 | — | — | US | disclosed |
| EP-3819293-A1 | ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR | Shandong Danhong Pharmaceutical Co., Ltd. (CN) | 2021-05-12 | — | — | EP | disclosed |
| US-20200102275-A1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102275-A1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | AGTR2, AGTR1, HCAR2 | CYP2D6 873/4885LMNA 4457/4885BLM 4846/4885 |
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | AGTR2, AGTR1, HCAR2 | CYP2D6 873/4885LMNA 4457/4885BLM 4846/4885 |
| US-20210206724-A1 | ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR | AGTR2, AGTR1, AVPR2 | CYP2D6 1187/4885LMNA 4112/4885BLM 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.